SUCCINYLCHOLINE CHLORIDE
PeakNDAINTRAMUSCULAR, INTRAVENOUSSOLUTION
Approved
Aug 2021
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
4/8 — Partial
SUCCINYLCHOLINE CHLORIDE by Hikma is blocker. Approved for mechanical ventilation. First approved in 2021.
Drug data last refreshed 6h ago · AI intelligence enriched 2mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Succinylcholine chloride is a depolarizing neuromuscular blocking agent that binds to acetylcholine receptors at the motor end plate, causing rapid onset flaccid paralysis within one minute. It is indicated for mechanical ventilation support in acute care settings. The drug's effects are short-lived, lasting approximately 4–6 minutes after intravenous administration.
Peak15.4 years to LOE
Product is at peak commercial stage with stable inpatient demand; team size likely moderate with focus on hospital/ICU relationships.
Mechanism of Action
blocker. As does acetylcholine, it combines with the cholinergic receptors of the motor end plate to produce depolarization. This depolarization may be observed as fasciculations. Subsequent neuromuscular transmission is inhibited so long as adequate concentration of succinylcholine remains at the…
Indications (1)
Worked on SUCCINYLCHOLINE CHLORIDE at Hikma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.